View pictures in App save up to 80% data.
Iconovo, which develops inhalable drugs based on proprietary inhalers and dry powder formulations, reports that it and Lonza initiated a collaboration to develop spray-dried formulations of an intranasal biologic for Iconovo’s proprietary intranasal device ICOone Nasal®. This project, with a reformulated substance for obesity, is the first in Iconovo’s strategic initiative to reformulate known pharmaceuticals and replace injections and oral treatments with inhalation.
Lonza will develop spray-dried formulations for administration in the ICOone Nasal device at its Bend, OR, which specializes in addressing bioavailability challenges and modulating pharmacokinetics to meet target product profiles. The collaboration aims to identify the ideal product properties concerning particle size, stability, and device compatibility while preserving biological activity.
The ICOone Nasal, part of the Iconovo inhaler platform, is designed to deliver medication through the nasal route by releasing the dose upon inhalation. With just one inhaler, users can take a dose by inhaling through each nostril, offering a potential alternative to current injectable formulations of biologic compounds.
"According to Johan Wäborg, CEO of Iconovo, 'Lonza stands as a global frontrunner in enhancing bioavailability and is widely recognized for its expertise in the spray-drying of biologics. When paired with Iconovo's innovative nasal inhaler, we anticipate creating a groundbreaking product that prioritizes patient convenience. We are optimistic that this partnership will evolve into a successful, enduring collaboration that extends beyond this particular initiative.'"
Kim Shepard, director of advanced drug delivery, stated, “Our team at Lonza’s respiratory center of excellence in Bend is excited to collaborate with Iconovo on its groundbreaking applications, merging Lonza’s expertise in particle engineering with Iconovo’s devices. Both companies share a commitment to providing non-invasive and accessible therapies to patients who need them.”
